LEFLUNOMIDE (Arava)
Pharmacology.
Leflunomide’s active metabolite (M1) inhibits dihydro-oratate dehydrogenase, thereby inhibiting pyrimidine biosynthesis. M1 exhibits immunomodulating and anti-inflammatory effects.
Administration and Adult Dosage.
PO for rheumatoid arthritis 100 mg/day for 3 days, then 20 mg/day. Reduce dose to 10 mg if 20 mg is not tolerated.
Pediatric Dosage.
Safety and efficacy not established.
Geriatric Dosage.
Same as adult dosage.
Dosage Forms.